Email page PDF view Print view Email Alert Social Media Sharing

Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand

Company Release - 6/28/2018 7:30 AM ET

WALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into an agreement with Purolite Life Sciences to supply its next-generation Protein A ligand, NGL-Impact™ A,  which will be commercialized by Purolite Life Sciences using their novel Praesto® agarose jetting base bead technology. Repligen is a longtime market leader in Protein A, with two facilities that produce the majority of the global Protein A ligand demand to biopharmaceutical customers worldwide.

NGL-Impact™ A was developed as part of Repligen’s collaboration with Navigo Proteins GmbH. This new ligand has outstanding performance attributes when immobilized on jetted agarose bead technology, with ultra-high binding capacities and excellent alkaline stability. These attributes are important in providing improved monoclonal antibody capture to handle increased upstream product titres, and in allowing higher concentrations of sodium hydroxide (NaOH) for sanitization of resins.

Purolite Life Sciences’s jetting technology is a new patented method that produces agarose beads with a uniform particle size distribution to drive higher capacity and increase pressure flow properties.  

Tony J. Hunt, Repligen CEO, said, “We are delighted by this agreement with Purolite Life Sciences, which is a natural extension of our existing Protein A supply agreement with them. We look forward to seeing how this next-generation ligand performs in the marketplace with Purolite Life Sciences’s Praesto® jetted agarose bead technology.”

Chris Major, VP of Sales for Purolite Life Sciences said, “We are pleased that Repligen has chosen Purolite Life Sciences to commercialize their next generation ligand. We’ve been very impressed in evaluations by the ligand’s overall performance characteristics, particularly the high binding capacity and caustic stability features that are so important to an efficient biologics manufacturing process. We look forward to continuing a productive relationship with Repligen and adding this ligand technology into our suite of products.”

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes protein products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and filtration products (including XCell™ ATF systems, TangenX™ Sius™ flat sheet TFF cassettes, and Spectrum KrosFlo™ hollow fiber TFF cartridges and systems). The Protein A ligands and growth factor products that we produce are essential components of Protein A affinity resins and cell culture media, respectively. Protein A affinity resins are the industry standard for downstream separation and purification of monoclonal antibody-based therapeutics. Our growth factors are used in upstream processes to accelerate cell growth and productivity in a bioreactor. Our innovative line of OPUS® chromatography columns, used in downstream processes for bench-scale through clinical-scale purification needs, are delivered pre-packed to our customers with their choice of resin. Our XCell™ ATF Systems, available in stainless steel and single-use configurations, are used upstream to continuously eliminate waste from a bioreactor, to concentrate cells and increase product yield. Single-use Sius™ TFF cassettes and hardware are used for biologic drug concentration in downstream filtration processes. Spectrum KrosFlo™ TFF cartridges and systems are used in both upstream and downstream filtration processes. Repligen’s corporate headquarters are in Waltham, MA (USA), with additional administrative and manufacturing operations in Shrewsbury, MA, Rancho Dominguez, CA, Lund, Sweden and Ravensburg, Germany.

About Purolite Life Sciences Life Sciences 
Purolite is a leading manufacturer of quality ion exchange, catalyst, adsorbent and specialty high-performance resins headquartered in Bala Cynwyd, PA and is the only company that focuses 100% of its resources on the development and production of resin technology.  Founded in 1981, Purolite has close to four decades of resin innovation and manufacturing experience and more than twenty-five years’ regulatory experience.  As a trusted supplier of resin to the world’s most regulated industries, Purolite has global manufacturing facilities in the USA, Asia and Europe.  Leveraging close to 40 years of resin expertise, Purolite Life Sciences offers a range of bioprocess scale high flow agarose resins for the purification of monoclonal antibodies and recombinant proteins.  The Praesto® product portfolio improves DSP efficiencies while reducing both clinical development and the manufacturing cost of biological therapeutics. Please visit www.purolitelifesciences.com for more information.                                          

The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements regarding Repligen’s partnership with Purolite Life Sciences, the performance attributes of Repligen’s Protein A ligands, and demand for Repligen’s Protein A ligands or the products into which they are incorporated constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to successfully grow our bioprocessing business, including as a result of acquisition, commercialization or partnership opportunities; our ability to successfully integrate any acquisitions, our ability to develop and commercialize products and the market acceptance of our products; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our compliance with all Food and Drug Administration and EMEA regulations; our volatile stock price; and other risks detailed in Repligen’s most recent Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.  

Repligen Contact: 
Sondra S. Newman
Senior Director Investor Relations
(781) 419-1881

Primary Logo

Source: Repligen Corporation